Eight-year-old Tyler Armstrong’s goal is to become the second youngest person ever to summit Mt. Kilimanjaro. Tyler, of Yorba Linda, Calif., is climbing Mt. Kilimanjaro to raise awareness and funds to find a cure for Duchenne muscular dystrophy. He already set a record as the youngest person to climb Mt. Whitney in California in a single day – the highest peak in the contiguous United States. While Tyler takes on the physical challenge of the climb from June 25 – July 2, 2012, he challenges others to donate a dollar to CureDuchenne for every foot he climbs.
“I’m climbing 19,341 feet to the top of Mt. Kilimanjaro for boys with Duchenne who can’t,” said Tyler. “If people donate one dollar for every foot I climb, we can raise a lot of money to help find a cure for Duchenne.” As the most common and lethal form of muscular dystrophy, Duchenne impacts one in 3,500 boys. Boys with Duchenne are usually diagnosed by the age of 5, in a wheelchair by age 12 and most don’t survive their mid-20s.
CureDuchenne (CureDuchenne.org) is a nonprofit organization dedicated to funding research to find treatments, and ultimately a cure, so that this generation of those impacted with Duchenne can be saved. Tyler’s climb is being coordinated through CureDuchenne, as part of the fourth annual Climb to CureDuchenne: Pick Your Peak event. The funds raised for Climb to CureDuchenne support the most promising research projects aimed at treating and curing Duchenne.
Others can participate in Climb to CureDuchenne: Pick Your Peak by choosing any mountain, hill or tall building to climb on June 23 or June 30, 2012. To learn more about Tyler visit TopWithTyler.com. To support Tyler and help him reach his $19,341 fundraising goal, donate here.
Travel Dirty is the official travel sponsor for the Mt. Kilimanjaro climb. The international travel agency caters to those who want their vacations to include both stunning locations and athletic adventures.
CureDuchenne is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide.
CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne. With the help of CureDuchenne’s distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have made their way into human clinical trials – a unique accomplishment as few health-related nonprofits have been successful in being a catalyst for human clinical trials.